Treatment of idiopathic short stature
Idiopathic short stature is treated by giving injections of growth hormone. The treatment continues until the child reaches his or her adult genetic potential height or until the growing ends of their bones fuse.
Genentech products approved for the treatment of idiopathic short stature
Nutropin AQ and Nutropin are also indicated for the long-term treatment of idiopathic short stature, also called non-growth hormone-deficient short stature, defined by height SDS <-2.25, and associated with growth rates unlikely to permit attainment of his or her adult genetic potential height, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.To learn more, click on the names of the products below—and be sure to discuss them with your healthcare provider.
Nutropin AQ Pen 10 for use with Nutropin AQ Pen 10 Cartridge: The latest innovation from Genentech's growth hormone product line, the Nutropin AQ Pen 10 offers simple delivery of Nutropin AQ, convenient transport, and enhanced safety features. Nutropin AQ Pen 10 is available in the U.S. by prescription only.
Nutropin AQ: A liquid GH that is premixed and ready for immediate injection. Unlike lyophilized (powdered) forms of GH, no mixing is necessary. Nutropin AQ makes GH therapy easier by eliminating about half the steps required to prepare lyophilized GH.
Nutropin: A lyophilized powder formulation that is reconstituted, or mixed, with Bacteriostatic water prior to an injection.
See Complete Indications and Important Safety Information
Back to top
